{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:39:39Z","timestamp":1766075979358,"version":"3.48.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2022110011"],"award-info":[{"award-number":["H2022110011"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ygyno.2025.10.035","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T23:23:24Z","timestamp":1763249004000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity"],"prefix":"10.1016","volume":"204","author":[{"given":"Meng","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.10.035_bb0005","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/aps.2010.103","article-title":"Poly (ADP-ribose) polymerase inhibitors as promising cancer therapeutics","volume":"31","author":"He","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.035_bb0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2025.10.035_bb0020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/bjc.2011.8","article-title":"A phase I study of the safety and tolerability of Olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumors","volume":"104","author":"Khan","year":"2011","journal-title":"Briti. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.10.035_bb0025","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","article-title":"An update on poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in Cancer therapy","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0030","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0035","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acs.jnatprod.2c00036","article-title":"Discovery of anticancer agents of diverse natural origin","volume":"85","author":"Aldrich","year":"2022","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0040","doi-asserted-by":"crossref","first-page":"8367","DOI":"10.3390\/molecules27238367","article-title":"Natural products as anticancer agents: current status and future perspectives","volume":"27","author":"Naeem","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ygyno.2025.10.035_bb0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/np068054v","article-title":"Natural products as sources of new drugs over the last 25 years","volume":"70","author":"Newman","year":"2007","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102961","article-title":"New perspective on the metabolism of AD-1 in vivo: characterization of a series of dammarane-type derivatives with novel metabolic sites and anticancer mechanisms of active oleanane-type metabolites","volume":"88","author":"Ding","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131016","article-title":"Simultaneous quantification and ADME prediction of AD-1 and its eight metabolites in rat feces, and screening of PARP-1 inhibitors through molecular docking","volume":"1244","author":"Ding","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12929-020-00684-5","article-title":"Dissecting the conformation of glycans and their interactions with proteins","volume":"27","author":"Wang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0065","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.1021\/acs.analchem.0c02304","article-title":"Complexation with a cognate antibody fragment facilitates affinity measurements of fluorescein-linked small molecule ligands","volume":"92","author":"Catalano","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12929-022-00889-w","article-title":"Conformational alteration in glycan induces phospholipase C\u03b21 activation and angiogenesis","volume":"29","author":"Wang","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0075","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1002\/ptr.6788","article-title":"Piperlongumine inhibits head and neck squamous cell carcinoma proliferation by docking to Akt","volume":"34","author":"Lv","year":"2020","journal-title":"Phytother. Res."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0080","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12916-020-01663-1","article-title":"Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus","volume":"18","author":"Yuan","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0085","doi-asserted-by":"crossref","unstructured":"D.V. Ferraris, Evolution of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic, J. Med. Chem. 53 (2010) 4561\u201384. doi: 10.1021\/ jm100012m.","DOI":"10.1021\/jm100012m"},{"key":"10.1016\/j.ygyno.2025.10.035_bb0090","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: setting paradigms in personalized cancer care and prevention","volume":"343","author":"Couch","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2025.10.035_bb0095","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1535-7163.MCT-13-0629","article-title":"MCL-1 degradation mediated by JNK activation via MEKK1\/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2025.10.035_bb0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ijc.25661","article-title":"MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation","volume":"129","author":"Zhang","year":"2011","journal-title":"Int. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582501073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582501073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:35:11Z","timestamp":1766075711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582501073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"alternative-id":["S009082582501073X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.035","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}